FDA Panel Supports Lower Acetaminophen Dose But Spares Combo Products
This article was originally published in The Pink Sheet Daily
Executive Summary
In what could be a major blow to manufacturers, acetaminophen sold in 500 mg tablets will come off the OTC market if FDA follows a joint advisory committee's recommendations, but the industry may be spared the additional pain of losing combination products that include acetaminophen and other ingredients.
You may also be interested in...
Cadence Builds Case For Branded IV Acetaminophen; Can It Reduce Opioid Use?
After rebounding from regulatory setbacks, Cadence Pharmaceuticals Inc. intravenous acetaminophen Ofirmev has been approved by FDA with a label many analysts praise as broad and positive.
Cadence Builds Case For Branded IV Acetaminophen; Can It Reduce Opioid Use?
After rebounding from regulatory setbacks, Cadence Pharmaceuticals Inc. intravenous acetaminophen Ofirmev has been approved by FDA with a label many analysts praise as broad and positive.
Cumberland Pharmaceuticals Raises $85 Million In IPO
First public offering for the pharmaceutical sector in 21 months suggests a financial thaw, but unlikely to spark an additional flood of deals.